VisionCare Anticipates Big Boost From Expanded Telescope Implant Indication
This article was originally published in The Gray Sheet
Executive Summary
FDA approved VisionCare Ophthalmic Technologies’ Implantable Miniature Telescope to treat macular degeneration in 65- to 74-year-old patients, expanding on the original 75-and-older indication and growing the potential market by about a third.
You may also be interested in...
People Briefs: CryoLife, VisionCare, Nihon Kohden, Nephros
CryoLife Executive Chairman retires. VisionCare Ophthalmic Technologies and Nihon Kohden, appoint new CEOs; Nephros appoints new leadership.
Retinal Disease: Much Progress, Some Pain
On many fronts, 2011 was an event-filled year for the retinal disease market, beginning with the publication of the CATT trial comparing off-label intravitreal Avastin versus Lucentis for the treatment of AMD, and ending with several important milestones for device manufacturers operating in this space. But while the retinal device field is making progress in many areas, companies continue to struggle to meet shifting FDA approval requirements.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.